Skip to main content
Clinical Trials/NCT01000337
NCT01000337CompletedNot Applicable

The Impact of Sevoflurane and Propofol Anesthesia on Hepatic Apoptosis Markers

University of Athens1 site in 1 country67 target enrollmentStarted: October 2009Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
67
Locations
1
Primary Endpoint
Changes in the M30 and M65 Markers Related to the Anesthesia Type

Study Overview

Brief Summary

Anesthesia may affect the function of vital organs. Liver is one of them. The investigator's hypothesis is that intravenous or inhalation anesthesia does not impair liver function as assessed by more elegant tests like markers indicating liver apoptosis. In the present randomized prospective trial female patients scheduled for mastectomy or thyroidectomy will receive inhalation or total intravenous anesthesia and markers for liver dysfunction will be determined.

Detailed Description

Female patients undergoing mastectomy or thyroidectomy under sevoflurane or propofol anesthesia will be recruited for the study. The type of anesthesia will be determined in a random way using a computer generated table.

All patients will be preoxygenated for 3 minutes before induction of anesthesia. Patients assigned to the sevoflurane group will receive an inhalation induction with sevoflurane via a primed anesthetic circle system and anesthesia will be maintained with sevoflurane. In the propofol group patients anaesthesia will be induced and maintained with propofol.

Blood samples for liver apoptotic markers will be collected before induction of anesthesia, after skin closure as well as 24 and 48 hours postoperatively.

Blood samples will be centrifuged, stored at -80 degrees Celsius and analyzed for M30 and M60 values with radioimmunoassay technique. Serum glutamic pyruvic transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) levels will also be determined.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
30 Years to 65 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Female patients aged between 30 and 65 years old scheduled for thyroidectomy or breast surgery for cancer

Exclusion Criteria

  • Drug intake which may affect liver function
  • Severe cardiovascular or respiratory disease
  • Hepatic or renal dysfunction
  • Pregnancy
  • Alcohol and drug abuse
  • Body Mass Index (BMI) > 35

Arms & Interventions

sevoflurane

Active Comparator

Volatile anesthetic

Intervention: Sevoflurane (Drug)

Propofol

Active Comparator

Intravenous anesthetic

Intervention: Propofol (Drug)

Outcomes

Primary Outcomes

Changes in the M30 and M65 Markers Related to the Anesthesia Type

Time Frame: preoperatively, end of surgery, 24 and 48 hours postoperatively

Blood samples for determination of the markers M30 and M65 as well as the serum transaminases were collected preoperatively, at the end of surgery, 24 and 48 hours postoperatively.

Secondary Outcomes

  • Transaminases(February 2011)

Investigators

Sponsor
University of Athens
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Argyro Fassoulaki

MD, PhD, DEAA

University of Athens

Study Sites (1)

Loading locations...

Similar Trials